| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 11 | 2023 | 342 | 2.080 |
Why?
|
| Fibrinolytic Agents | 12 | 2018 | 324 | 1.920 |
Why?
|
| Transcatheter Aortic Valve Replacement | 9 | 2021 | 314 | 1.620 |
Why?
|
| Myocardial Infarction | 22 | 2020 | 1374 | 1.530 |
Why?
|
| Emergency Medical Services | 9 | 2020 | 429 | 1.440 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2011 | 314 | 1.420 |
Why?
|
| Thrombolytic Therapy | 10 | 2018 | 257 | 1.310 |
Why?
|
| Aortic Valve Stenosis | 9 | 2021 | 476 | 1.250 |
Why?
|
| Coronary Artery Disease | 6 | 2023 | 1011 | 1.140 |
Why?
|
| Embolism | 2 | 2018 | 59 | 1.100 |
Why?
|
| Coronary Occlusion | 2 | 2018 | 31 | 1.080 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 5 | 0.950 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 259 | 0.900 |
Why?
|
| ST Elevation Myocardial Infarction | 3 | 2020 | 105 | 0.860 |
Why?
|
| Cardiology | 6 | 2023 | 530 | 0.820 |
Why?
|
| Coronary Artery Bypass | 5 | 2023 | 708 | 0.680 |
Why?
|
| Embolism, Fat | 1 | 2018 | 8 | 0.650 |
Why?
|
| Denervation | 1 | 2017 | 33 | 0.610 |
Why?
|
| Lipectomy | 1 | 2018 | 63 | 0.610 |
Why?
|
| Coronary Angiography | 13 | 2023 | 598 | 0.590 |
Why?
|
| Aortic Valve | 7 | 2021 | 581 | 0.580 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 1237 | 0.550 |
Why?
|
| Myocardial Reperfusion | 3 | 2011 | 108 | 0.550 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 435 | 0.510 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 655 | 0.500 |
Why?
|
| Angina Pectoris | 4 | 2021 | 80 | 0.470 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 167 | 0.470 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 603 | 0.460 |
Why?
|
| Endocarditis, Bacterial | 1 | 2014 | 128 | 0.430 |
Why?
|
| Foramen Ovale, Patent | 2 | 2022 | 22 | 0.430 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 183 | 0.420 |
Why?
|
| Septal Occluder Device | 2 | 2022 | 49 | 0.410 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 152 | 0.410 |
Why?
|
| Coronary Vessels | 9 | 2023 | 665 | 0.400 |
Why?
|
| Treatment Outcome | 32 | 2023 | 32848 | 0.390 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2018 | 444 | 0.370 |
Why?
|
| Recovery of Function | 1 | 2014 | 703 | 0.370 |
Why?
|
| Electrocardiography | 5 | 2020 | 1145 | 0.370 |
Why?
|
| Humans | 75 | 2023 | 261506 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 563 | 0.340 |
Why?
|
| Cardiac Catheterization | 8 | 2022 | 687 | 0.340 |
Why?
|
| Kidney | 1 | 2017 | 2146 | 0.320 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 50 | 0.320 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1274 | 0.320 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 672 | 0.320 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 131 | 0.310 |
Why?
|
| Stroke | 4 | 2022 | 1144 | 0.300 |
Why?
|
| Critical Care | 1 | 2013 | 770 | 0.300 |
Why?
|
| Myocardial Ischemia | 1 | 2011 | 435 | 0.300 |
Why?
|
| Stents | 7 | 2009 | 1096 | 0.290 |
Why?
|
| Chest Pain | 2 | 2023 | 155 | 0.280 |
Why?
|
| Heart Failure | 4 | 2022 | 2516 | 0.270 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 267 | 0.260 |
Why?
|
| Veterans | 3 | 2021 | 1641 | 0.250 |
Why?
|
| Theft | 1 | 2023 | 5 | 0.240 |
Why?
|
| Hemodynamics | 3 | 2022 | 935 | 0.230 |
Why?
|
| United States | 17 | 2023 | 15433 | 0.230 |
Why?
|
| Hospitals, Low-Volume | 2 | 2021 | 53 | 0.230 |
Why?
|
| Coronary Disease | 5 | 2016 | 764 | 0.230 |
Why?
|
| Subclavian Artery | 1 | 2023 | 80 | 0.230 |
Why?
|
| Atrial Flutter | 1 | 2022 | 21 | 0.220 |
Why?
|
| Coronary Restenosis | 3 | 2009 | 63 | 0.220 |
Why?
|
| Risk Factors | 16 | 2022 | 17523 | 0.200 |
Why?
|
| Coronary Circulation | 4 | 2008 | 253 | 0.200 |
Why?
|
| Hypothermia | 1 | 2021 | 59 | 0.200 |
Why?
|
| Atherectomy, Coronary | 2 | 2020 | 16 | 0.200 |
Why?
|
| Ischemia | 2 | 2021 | 391 | 0.200 |
Why?
|
| Triage | 2 | 2020 | 252 | 0.200 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2022 | 62 | 0.200 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 610 | 0.190 |
Why?
|
| Angina, Unstable | 3 | 2006 | 70 | 0.190 |
Why?
|
| Reoperation | 3 | 2020 | 1382 | 0.190 |
Why?
|
| Myocardium | 1 | 2007 | 1313 | 0.190 |
Why?
|
| American Heart Association | 4 | 2023 | 310 | 0.180 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 89 | 0.180 |
Why?
|
| Benchmarking | 1 | 2022 | 273 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.180 |
Why?
|
| Aged | 24 | 2023 | 70117 | 0.180 |
Why?
|
| Pericarditis | 1 | 2020 | 61 | 0.180 |
Why?
|
| Coronary Stenosis | 1 | 2021 | 117 | 0.180 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 33 | 0.180 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.180 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 77 | 0.170 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 94 | 0.170 |
Why?
|
| Giardiasis | 1 | 1998 | 15 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 2403 | 0.170 |
Why?
|
| Societies, Medical | 5 | 2023 | 1335 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 228 | 0.160 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 48 | 0.160 |
Why?
|
| Inpatients | 2 | 2020 | 678 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 180 | 0.160 |
Why?
|
| Female | 32 | 2020 | 141928 | 0.160 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 318 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2020 | 732 | 0.150 |
Why?
|
| Clinical Competence | 5 | 2023 | 1270 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 251 | 0.150 |
Why?
|
| Echocardiography | 3 | 2019 | 1182 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 473 | 0.140 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2006 | 13 | 0.140 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 193 | 0.140 |
Why?
|
| Atrial Pressure | 1 | 2016 | 6 | 0.140 |
Why?
|
| Heart Septum | 1 | 2016 | 54 | 0.140 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 31 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 1303 | 0.140 |
Why?
|
| Hypertension | 3 | 2017 | 1503 | 0.140 |
Why?
|
| Quality Improvement | 2 | 2020 | 851 | 0.140 |
Why?
|
| Male | 30 | 2020 | 123000 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 665 | 0.140 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 605 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2019 | 6869 | 0.140 |
Why?
|
| Time Factors | 10 | 2021 | 12926 | 0.130 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 142 | 0.130 |
Why?
|
| Fever | 1 | 1998 | 497 | 0.130 |
Why?
|
| Guideline Adherence | 2 | 2018 | 636 | 0.130 |
Why?
|
| Heart Transplantation | 2 | 2020 | 908 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 2594 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 761 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 719 | 0.130 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 516 | 0.130 |
Why?
|
| Diarrhea | 1 | 1998 | 686 | 0.130 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 192 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2017 | 1467 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1559 | 0.120 |
Why?
|
| Echocardiography, Doppler | 2 | 2007 | 180 | 0.120 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 4298 | 0.120 |
Why?
|
| Weight Loss | 1 | 1998 | 627 | 0.120 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2014 | 69 | 0.120 |
Why?
|
| Medical Staff | 1 | 2013 | 9 | 0.120 |
Why?
|
| Comorbidity | 4 | 2020 | 2352 | 0.120 |
Why?
|
| Nurse's Role | 1 | 2013 | 42 | 0.120 |
Why?
|
| Brain Ischemia | 1 | 2016 | 292 | 0.120 |
Why?
|
| Drug Substitution | 1 | 2013 | 87 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 671 | 0.110 |
Why?
|
| Pharmacists | 1 | 2013 | 95 | 0.110 |
Why?
|
| Nurses | 1 | 2013 | 80 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 1999 | 705 | 0.110 |
Why?
|
| Registries | 4 | 2021 | 2170 | 0.110 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2004 | 100 | 0.110 |
Why?
|
| Heart | 3 | 2023 | 1223 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 280 | 0.100 |
Why?
|
| Emergencies | 1 | 2013 | 202 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 551 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 386 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2019 | 5542 | 0.100 |
Why?
|
| Transportation of Patients | 1 | 2011 | 59 | 0.100 |
Why?
|
| Tachycardia, Ventricular | 1 | 2014 | 239 | 0.100 |
Why?
|
| Time | 1 | 2011 | 178 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2016 | 620 | 0.100 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 308 | 0.100 |
Why?
|
| Middle Aged | 22 | 2020 | 86204 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1171 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2016 | 2316 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 1429 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 756 | 0.090 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 164 | 0.090 |
Why?
|
| Recurrence | 3 | 2022 | 4758 | 0.090 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 101 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2014 | 358 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 244 | 0.080 |
Why?
|
| Postoperative Care | 1 | 2013 | 739 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2022 | 329 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 941 | 0.080 |
Why?
|
| Aspirin | 3 | 2018 | 455 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 4744 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 849 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2009 | 204 | 0.080 |
Why?
|
| Fibrinolysis | 1 | 2008 | 63 | 0.080 |
Why?
|
| Vascular Patency | 1 | 2008 | 218 | 0.080 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 4320 | 0.080 |
Why?
|
| Calcinosis | 2 | 2001 | 423 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 395 | 0.070 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 2315 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2195 | 0.070 |
Why?
|
| Blood Flow Velocity | 2 | 2009 | 475 | 0.070 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 29902 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 343 | 0.070 |
Why?
|
| Vasodilator Agents | 2 | 2004 | 219 | 0.070 |
Why?
|
| Hospitalization | 3 | 2020 | 2083 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 891 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2004 | 48 | 0.060 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 3719 | 0.060 |
Why?
|
| Heparin | 2 | 2007 | 360 | 0.060 |
Why?
|
| Wounds, Penetrating | 1 | 2004 | 89 | 0.060 |
Why?
|
| Survival Rate | 5 | 2020 | 12221 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 2018 | 467 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1085 | 0.050 |
Why?
|
| Adenosine | 1 | 2004 | 289 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 61 | 0.050 |
Why?
|
| Retrospective Studies | 8 | 2021 | 37905 | 0.050 |
Why?
|
| Ultrasonography, Interventional | 1 | 2004 | 429 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 8865 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 649 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2001 | 135 | 0.050 |
Why?
|
| Thrombin | 1 | 2001 | 99 | 0.050 |
Why?
|
| Atherectomy | 1 | 2020 | 12 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2001 | 95 | 0.050 |
Why?
|
| Limb Salvage | 1 | 2021 | 162 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 482 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 354 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 140 | 0.050 |
Why?
|
| Vascular Calcification | 1 | 2020 | 50 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 155 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2019 | 46 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 257 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2021 | 846 | 0.040 |
Why?
|
| Cause of Death | 2 | 2016 | 752 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 130 | 0.040 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 88 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 74 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 14889 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 77950 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 305 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1999 | 133 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2020 | 271 | 0.040 |
Why?
|
| Brachytherapy | 1 | 2004 | 977 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 5377 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2019 | 362 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 629 | 0.040 |
Why?
|
| Thrombosis | 1 | 2003 | 781 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2019 | 2218 | 0.040 |
Why?
|
| Hepatomegaly | 1 | 2016 | 69 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 649 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 4938 | 0.030 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 714 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 945 | 0.030 |
Why?
|
| Survivors | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 4892 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 126 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 289 | 0.030 |
Why?
|
| Ascites | 1 | 2016 | 198 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 390 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 548 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 227 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 7702 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 267 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 246 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2139 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 860 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 577 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 661 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 15193 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 429 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 1230 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 1204 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1900 | 0.030 |
Why?
|
| Population Density | 1 | 2011 | 38 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2009 | 2588 | 0.030 |
Why?
|
| North America | 1 | 2011 | 314 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 787 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2014 | 12873 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 261 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 430 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2004 | 1546 | 0.020 |
Why?
|
| Incidence | 2 | 2014 | 5673 | 0.020 |
Why?
|
| Prognosis | 4 | 2016 | 21713 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 5047 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 113 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 276 | 0.020 |
Why?
|
| Patient Selection | 1 | 2016 | 2055 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 348 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2001 | 7551 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 1054 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 330 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 1382 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 134 | 0.020 |
Why?
|
| Constriction | 1 | 2004 | 55 | 0.020 |
Why?
|
| Protamines | 1 | 2004 | 29 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 10001 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 1351 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2003 | 43 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2003 | 96 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 200 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 980 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2007 | 2292 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 409 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1323 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 2422 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 352 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2003 | 333 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 2803 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2006 | 1819 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 20 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 1972 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1999 | 121 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1148 | 0.010 |
Why?
|
| Exercise Test | 1 | 1999 | 312 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 1999 | 206 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1999 | 145 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 295 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 1085 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1999 | 1391 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 6100 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 1301 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 9180 | 0.010 |
Why?
|